Antibacterial Resistance Leadership Group (ARLG)

What Antibacterial Resistance Leadership Group (ARLG) does

The Antibacterial Resistance Leadership Group (ARLG) is a federally funded clinical research consortium established in 2013 to prioritize, design, and execute research on the prevention, diagnosis, and treatment of antibiotic-resistant bacterial infections. ARLG operates under cooperative agreement UM1AI104681 from the National Institute of Allergy and Infectious Diseases (NIAID) and is facilitated by the Duke Clinical Research Institute, with principal investigators Vance Fowler, MD (Duke University) and Henry "Chip" Chambers, MD (UCSF). The consortium comprises more than 165 leading experts organized around four component centers (Scientific Leadership Center, Clinical Operations Center, Laboratory Center at Mayo Clinic, and Statistical and Data Management Center at George Washington University and DCRI) and operates a global network of 165 clinical trial sites across 19 countries enrolling more than 28,000 participants.

ARLG's core offerings are research methodologies and resources rather than commercial products. These include the DOOR (Desirability of Outcome Ranking) framework, RADAR, SMART COMPASS, MASTERMIND protocol for multi-diagnostic evaluation, BED-FRAME/AWA diagnostic assessment tools, and the GENO-STELLAR Klebsiella pneumoniae genomic platform. The ARLG Biorepository at Mayo Clinic provides a web-searchable catalog of thousands of characterized bacterial isolates, and the organization runs more than 65 clinical studies producing 330+ peer-reviewed manuscripts. ARLG also runs the Dr. John G. Bartlett ARLG Fellowship and ESI grant programs, having supported more than 45 mentees who co-author 240+ publications. MASTERMIND-GC directly led to FDA clearance of new assays for extragenital gonorrhea and chlamydia testing.

ARLG's revenue model is grant-funded rather than commercial: NIH/NIAID cooperative agreement funding underwrites operations, mentoring, biorepository distribution (free of charge to approved researchers), and clinical trial execution. Industry collaborations with pharmaceutical and diagnostic companies, clinical trial site engagements, and protocol concept submissions are managed through formal application processes but do not appear to be a disclosed revenue source. Customer segments include early-stage investigators, ID fellows, academic and government researchers, and enterprise pharmaceutical and diagnostic companies, all served under the umbrella of publicly funded AMR research.

Name

Antibacterial Resistance Leadership Group (ARLG)

Legal name

Antibacterial Resistance Leadership Group

Website

https://arlg.org

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

101–250 employees

Short description

ARLG is an NIH/NIAID-funded clinical research consortium, facilitated by Duke, that designs and executes multi-center studies on antibacterial resistance across 165 sites in 19 countries. It develops proprietary trial methodologies (DOOR, MASTERMIND), operates a characterized bacterial isolate biorepository at Mayo Clinic, and trains early-career AMR investigators.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (541690)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Hospital Epidemiology & Infection Prevention (HLAKAGAF)

akta.pro secondary industry

General Infectious Disease (HLAKAGAA)

Keywords

• Clinical research consortium
• Antibacterial resistance research
• Infectious disease trials
• Bacterial isolate biorepository
• Antimicrobial clinical studies

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. NIH/NIAID Research Funding: ARLG receives its primary funding from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health, under Award Number UM1AI104681. This grant funds the consortium's operations, research activities, mentoring programs, clinical trials, and administrative functions.

Pricing tiers

Go-to-market motion2 records

Distribution channels6 records

Marketing channels6 records

Core offering

ARLG is an NIH-funded clinical research consortium that prioritizes, designs, and executes multi-center clinical studies on the prevention, diagnosis, and treatment of infections caused by antibiotic-resistant bacteria. It develops proprietary research methodologies (DOOR, MASTERMIND, SMART COMPASS, RADAR), maintains a curated bacterial isolate biorepository at Mayo Clinic, and provides statistical/data management support, fellowships, ESI grants, and industry collaboration services to advance antibacterial resistance science.

Product overview

The Antibacterial Resistance Leadership Group (ARLG) is a research consortium (not a commercial product company) consisting of more than 165 leading experts working to combat antibacterial resistance. ARLG's offerings center on clinical research studies and innovative research methodology tools. The core research tools include: DOOR (Desirability of Outcome Ranking) for patient-centric benefit-risk evaluation in clinical trials; RADAR for antibiotic optimization strategies; SMART COMPASS for adaptive clinical trial designs; MASTERMIND protocol for evaluating multiple diagnostic tests simultaneously; and BED-FRAME/AWA for diagnostic test assessment. Supporting infrastructure includes the ARLG Biorepository (bacterial isolate collection housed at Mayo Clinic), the Statistical and Data Management Center (at George Washington University and Duke), and the Laboratory Center. ARLG also provides fellowship and grant programs for early-stage investigators and a data request program for researchers. The organization conducts numerous clinical studies addressing antibiotic-resistant bacterial infections.

Differentiator

Problem solved

Functional benefit

Brands

• MASTERMIND: MASTER Protocol for Evaluating Multiple Infection Diagnostics - a clinical trial design approach that uses a single subject's sample(s) to evaluate multiple diagnostic tests simultaneously
• DOOR
• GENO-STELLAR
• ARLG Biorepository

Products and services

• ARLG Biorepository

Quantifiable outcome

• More than 330 manuscripts published, with MASTERMIND-GC directly leading to new FDA-clearance of assays for extragenital gonorrhea and chlamydia testing
• +2 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature12 records

Partnerships

Five partnerships are on record, tiered core and supporting.

• Mayo CliniccoreStrategic or Co-development Partner · 1 January 2019Mayo Clinic houses the ARLG Laboratory Center and the physical Biorepository. Robin Patel, MD serves as Laboratory Center Director. The biorepository provides characterized bacterial isolates to researchers globally for diagnostic and therapeutic development.
• Duke Clinical Research Institute (DCRI)coreStrategic or Co-development Partner · 1 January 2013DCRI serves as the coordinating center and facilitator for ARLG operations. The Data Management and Informatics Center of the SDMC is located at DCRI. DCRI provides operational infrastructure, project management, and administrative support for the consortium.
• George Washington University Milken Institute School of Public HealthcoreStrategic or Co-development Partner · 1 January 2013The SDMC Statistics and Data Analysis Center is located at George Washington University. Scott Evans, PhD leads the SDMC from this location, providing expert statistical leadership, data monitoring, and innovative methodological development for ARLG studies.
• Duke University School of Medicine Clinical Research Training ProgramsupportingStrategic or Co-development Partner · 1 January 2013ARLG Fellowship recipients may receive formal training in epidemiology or statistics at Duke's Clinical Research Training Program. Costs for this coursework are covered by the ARLG as part of the fellowship package.
• 165 Clinical Trial SitescoreStrategic or Co-development Partner · 1 January 2013ARLG has activated 165 clinical trial sites across 19 countries with more than 28,000 participants. Sites include academic medical centers, community hospitals, and research institutions that conduct ARLG clinical studies.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Emerging players

• AMR Action Fund: Pharma-backed fund investing in clinical-stage antibiotic developers; comparable as an AMR-focused funding vehicle but oriented toward commercial biotech investment rather than academic trial execution.
• SENTRY Antimicrobial Surveillance Program (JMI Laboratories): Long-running global antimicrobial resistance surveillance and microbiological testing network; comparable in maintaining an AMR-specific specimen/isolate resource used by industry and academia, though focused on surveillance rather than interventional trials.

Direct peers

• IMPAACT Network: NIAID-funded clinical trials network using the same cooperative agreement and statistical data center framework as ARLG; directly comparable in operating model and investigator/site engagement.
• CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator): Global AMR-focused accelerator co-funded by BARDA and Wellcome that funds antibacterial R&D across academia and industry; directly comparable in mission to combat antibacterial resistance, though structured as a portfolio funder rather than a trial operator.
• ACTG (AIDS Clinical Trials Group): NIH/NIAID-funded multicenter clinical trials network that shares ARLG's cooperative-agreement funding model, multi-center trial infrastructure, and statistical center approach; comparable in scale, governance, and grant-dependence.
• GARDP (Global Antibiotic Research & Development Partnership): International AMR R&D initiative developing new antibiotic treatments; comparable in AMR focus and global, multi-stakeholder governance, with overlapping pharmaceutical industry partnerships.

Broad incumbents

• CTSA (Clinical and Translational Science Awards) Program: NCATS-led NIH network of ~60 academic medical centers running translational and clinical research; comparable as NIH-funded multi-site trial infrastructure but spanning all therapeutic areas, not specialized in AMR.
• IDSA (Infectious Diseases Society of America): Professional society whose members drive AMR clinical guidelines and research priorities; comparable as a convening authority in infectious disease with overlapping physician/researcher community and guideline influence.
• BARDA (Biomedical Advanced Research and Development Authority): HHS authority funding advanced development of medical countermeasures including antibiotics and diagnostics; comparable as a major federal AMR funder with overlapping diagnostic and antimicrobial partnerships.
• Wellcome Trust AMR Programs: Major charitable funder of AMR research including CARB-X and surveillance programs; comparable as a long-horizon AMR funder influencing global research priorities alongside NIH.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/ARLGnetwork
• LinkedInlp.constantcontactpages.com/su/2EiUvCU

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Antibacterial Resistance Leadership Group (ARLG)